163 related articles for article (PubMed ID: 32340124)
1. Apigenin Inhibits Histamine-Induced Cervical Cancer Tumor Growth by Regulating Estrogen Receptor Expression.
Zhang E; Zhang Y; Fan Z; Cheng L; Han S; Che H
Molecules; 2020 Apr; 25(8):. PubMed ID: 32340124
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells.
Yang J; Pi C; Wang G
Biomed Pharmacother; 2018 Jul; 103():699-707. PubMed ID: 29680738
[TBL] [Abstract][Full Text] [Related]
3. Apigenin, a Partial Antagonist of the Estrogen Receptor (ER), Inhibits ER-Positive Breast Cancer Cell Proliferation through Akt/FOXM1 Signaling.
Pham TH; Page YL; Percevault F; Ferrière F; Flouriot G; Pakdel F
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466512
[TBL] [Abstract][Full Text] [Related]
4. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
5. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
Ge X; Guo R; Qiao Y; Zhang Y; Lei J; Wang X; Li L; Hu D
Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
[TBL] [Abstract][Full Text] [Related]
6. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
[TBL] [Abstract][Full Text] [Related]
7. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
8. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
9. Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex class I-related chain A gene expression.
Xia C; Liu C; He Z; Cai Y; Chen J
J Exp Clin Cancer Res; 2020 Jul; 39(1):127. PubMed ID: 32631421
[TBL] [Abstract][Full Text] [Related]
10. Estrogen/GPR30 Signaling Contributes to the Malignant Potentials of ER-Negative Cervical Adenocarcinoma via Regulation of Claudin-1 Expression.
Akimoto T; Takasawa A; Takasawa K; Aoyama T; Murata M; Osanai M; Saito T; Sawada N
Neoplasia; 2018 Oct; 20(10):1083-1093. PubMed ID: 30227306
[TBL] [Abstract][Full Text] [Related]
11. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.
Tian J; Wang Y; Zhang X; Ren Q; Li R; Huang Y; Lu H; Chen J
J Exp Clin Cancer Res; 2017 Nov; 36(1):153. PubMed ID: 29096683
[TBL] [Abstract][Full Text] [Related]
12. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Sun H; Yin M; Qian W; Yin H
Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
[TBL] [Abstract][Full Text] [Related]
13. Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
Wei Y; Zhang Z; Liao H; Wu L; Wu X; Zhou D; Xi X; Zhu Y; Feng Y
Oncol Rep; 2012 Feb; 27(2):504-10. PubMed ID: 22075757
[TBL] [Abstract][Full Text] [Related]
14. Bisphenol A and estrogen induce proliferation of human thyroid tumor cells via an estrogen-receptor-dependent pathway.
Zhang Y; Wei F; Zhang J; Hao L; Jiang J; Dang L; Mei D; Fan S; Yu Y; Jiang L
Arch Biochem Biophys; 2017 Nov; 633():29-39. PubMed ID: 28882636
[TBL] [Abstract][Full Text] [Related]
15. Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: an in vitro and in vivo study.
Shukla S; Gupta S
Mol Carcinog; 2009 Mar; 48(3):243-252. PubMed ID: 18726972
[TBL] [Abstract][Full Text] [Related]
16. Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
Xia C; He Z; Cai Y; Liang S
Eur J Pharmacol; 2020 May; 875():173057. PubMed ID: 32135122
[TBL] [Abstract][Full Text] [Related]
17. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo.
Bao YY; Zhou SH; Lu ZJ; Fan J; Huang YP
Oncol Rep; 2015 Oct; 34(4):1805-14. PubMed ID: 26238658
[TBL] [Abstract][Full Text] [Related]
19. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.
Shukla S; Bhaskaran N; Babcook MA; Fu P; Maclennan GT; Gupta S
Carcinogenesis; 2014 Feb; 35(2):452-60. PubMed ID: 24067903
[TBL] [Abstract][Full Text] [Related]
20. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
